~~VIII. Claims~~

What is ~~Claimed~~claimed:

~~A method of~~

1. Use of a therapeutically effective amount of an LTA4H inhibitory agent that inhibits LTA4H aminopeptidase and epoxide hydrolase activity in the manufacture of a medicament for improving cognitive function in a subject diagnosed with an ~~age-related~~aging-associated cognitive ~~disease, the method comprising administering a therapeutically effective amount of an LTA4H modulatory agent.~~impairment caused by neuroinflammation.

2. The ~~method of~~ use according to claim 1 wherein the aging-associated cognitive ~~disease~~impairment caused by neuroinflammation is caused by a disease selected from the group consisting of Alzheimer's Disease, mild cognitive impairment, Parkinson's Disease, Parkinsonism, Frontotemporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, multiple sclerosis, dementia, dementia with Lewy bodies, and progressive supranuclear palsy.

3. The ~~method of~~ use according to claim 1 wherein the LTA4H ~~modulatory~~inhibitory agent is a small organic molecule antagonist to LTA4H.

4. The ~~method of~~ use according to claim 1 wherein the LTA4H ~~modulatory~~inhibitory agent is an antibody to LTA4H.

~~5. The method of claim 3 wherein the antagonist to LTA4H antagonizes the epoxide hydrolase activity of LTA4H.~~

~~6. The method of claim 3 wherein the antagonist to LTA4H antagonizes both the epoxide hydrolase activity and the aminopeptidase activity of LTA4H.~~

~~7.~~5.~~The method of~~use according to any of the preceding claims wherein the subject is a mammal.

~~8.~~6.The ~~method of~~ use according to claim ~~7~~5 wherein the mammal is a human.

~~9.~~7.~~A kit~~Use of a kit comprising an LTA4H inhibitory agent that inhibits LTA4H aminopeptidase and epoxide hydrolase activity in the manufacture of a medicament for ~~use in~~

improving cognitive ~~function~~impairment caused by neuroinflammation in a subject diagnosed with an ~~age-related~~aging-associated cognitive disease~~, the kit comprising an LTA4H modulatory agent.~~ .

~~10.~~8. The ~~kit of~~use according to claim ~~9~~7 wherein the LTA4H ~~modulatory~~inhibitory agent is a small organic molecule antagonist to LTA4H.

~~11.~~9. The ~~kit of~~use according to claim ~~9~~7 wherein the LTA4H ~~modulatory~~inhibitory agent is an antibody to LTA4H.

~~12. The kit of claim 11 wherein the antagonist to LTA4H antagonizes the epoxide hydrolase activity of LTA4H.~~

~~13. The kit of claim 12 wherein the antagonist to LTA4H antagonizes both the epoxide hydrolase activity and the aminopeptidase activity of LTA4H.~~